Harrison W Farber MD

Pulmonology•Boston, MA

Critical Care Medicine, Pleural Disease

Professor, Medicine, Boston University School of Medicine

Join to View Full Profile

725 Albany St# ShapiroBoston, MA 02118
Phone+1 617-638-7480
Fax+1 617-638-7486

Education & Training

Boston University Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1981 - 1984
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 1977 - 1980
George Washington University School of Medicine and Health SciencesClass of 1977

Certifications & Licensure

MA State Medical License 1981 - 2025
VA State Medical License 1978 - 2000
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Boston Magazine Castle Connolly, 2010-2013
Elected Member The American Society for Clinical Investigation, 1992
Top MD Consumers Checkbook

Clinical Trials

REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management Start of enrollment: 2006 Mar 01
Completed
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Start of enrollment: 2011 Jun 24
Completed
Phase 2
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension Start of enrollment: 2009 Dec 01
COMPLETED
PHASE3
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
Completed
Phase 3
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT Start of enrollment: 2014 May 31
Completed
Phase 2
Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction Start of enrollment: 2014 Jul 01
Completed
Phase 2
Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction Start of enrollment: 2011 Jul 01
Completed
Phase 4
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

Risk Assessment Tools in Pulmonary Arterial Hypertension: Why Can't We Be Friends?
Nicole F Ruopp, Harrison W Farber
Chest. 2024-11-01
Mechanical Preload Reduction: Harnessing a Cornerstone of Heart Failure Management to Improve Clinical Outcomes.
Navin K Kapur, Manreet K Kanwar, Rayan Yousefzai, Arvind Bhimiraj, Harrison Farber
ASAIO Journal. 2024-10-01
Fucosylation: The Prognostic Impact of Sugar in Pulmonary Arterial Hypertension.
Harrison W Farber, Noah C Schoenberg
Journal of the American College of Cardiology. 2024-09-17

Journal Articles

Serum Biomarker for Diagnostic Evaluation of Pulmonary Arterial Hypertension in Systemic Sclerosis
Harrison W Farber, Kari Roberts, Nicholas Hill, Robyn Domsic, Robert W Simms, BioMed Central

Lectures

10th International Pulmonary Hypertension Conference and Scientific Sessions
Pulmonary Hypertension Association, Orlando, Florida - 6/22/2012

Other

Pulmonary complications of sickle cell disease
Farber HW, Hammerman SI
http://www.uptodate.com/contents/pulmonary-complications-of-sickle-cell-disease
UpToDate, Wolters Kluwer Health - 2012-11-05
Foreign body granulomatosis
Farber HW, Hendra KP
http://www.uptodate.com/contents/foreign-body-granulomatosis
UpToDate, Wolters Kluwer Health - 2012-05-11
Pulmonary hypertension associated with human immunodeficiency virus
Farber HW, Ieong M
http://www.uptodate.com/contents/pulmonary-hypertension-associated-with-human-immunodeficiency-virus
UpToDate, Wolters Kluwer Health - 2012-09-06

Press Mentions

Pulmonary Arterial HypertensionJune 28th, 2016

Grant Support

Biomarkers Of Pulmonary Complications Of Scleroderma: The Ssc-Pah AndNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
Oxidant State And Nitric Oxide Metabolism In The Acute Chest SyndromeNational Heart, Lung, And Blood Institute2004–2007
Endothelial Cell Hypoxia Tolerance: Role Of PlasmalogensNational Heart, Lung, And Blood Institute2003–2006
Endothelial Cell Hypoxia Associated ProteinsNational Heart, Lung, And Blood Institute1997–2000
Endothelial Cell Hypoxia-Associated ProteinsNational Heart, Lung, And Blood Institute1993–1996
Endothelial Cell Derived Neutrophil ChemoattractantsNational Heart, Lung, And Blood Institute1985–1987

Other Languages

French